This inventor holds 4 USPTO granted patents. Top assignees: King Abdulaziz University, Virginia Commonwealth University. Active years: 2020-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 588 
2 out of 420 
Years Active: 2020-2022
Title: Abdelsattar Mansour Ebeid Omar: Innovator in Hypoxia Treatment
Introduction
Abdelsattar Mansour Ebeid Omar is a notable inventor based in Jeddah, Saudi Arabia. He has made significant contributions to the field of medical science, particularly in the treatment of hypoxia-related disorders. With a total of 4 patents, his work focuses on innovative solutions for serious health conditions.
Latest Patents
Among his latest patents, Abdelsattar has developed metabolically stable 5-HMF derivatives for the treatment of hypoxia. These 5-HMF derivative compounds are designed to bind covalently with hemoglobin, providing a novel approach to treating sickle cell disease and other disorders associated with hypoxia. His research offers promising methods for administering these compounds effectively.
Career Highlights
Abdelsattar has worked with prestigious institutions such as King Abdulaziz University and Virginia Commonwealth University. His experience in these organizations has allowed him to advance his research and contribute to the scientific community significantly.
Collaborations
He has collaborated with esteemed colleagues, including Moustafa El-Sayed El-Araby and Martin K Safo. These partnerships have enriched his research and expanded the impact of his innovations.
Conclusion
Abdelsattar Mansour Ebeid Omar is a pioneering inventor whose work in hypoxia treatment showcases his dedication to improving health outcomes. His innovative patents and collaborations highlight his significant role in advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile